IL158201A0 - Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine - Google Patents

Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Info

Publication number
IL158201A0
IL158201A0 IL15820102A IL15820102A IL158201A0 IL 158201 A0 IL158201 A0 IL 158201A0 IL 15820102 A IL15820102 A IL 15820102A IL 15820102 A IL15820102 A IL 15820102A IL 158201 A0 IL158201 A0 IL 158201A0
Authority
IL
Israel
Prior art keywords
cox
inhibitor
drug
solvent
pharmaceutical composition
Prior art date
Application number
IL15820102A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of IL158201A0 publication Critical patent/IL158201A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15820102A 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine IL158201A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28438101P 2001-04-17 2001-04-17
US32695201P 2001-10-04 2001-10-04
PCT/US2002/011689 WO2002083177A1 (en) 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Publications (1)

Publication Number Publication Date
IL158201A0 true IL158201A0 (en) 2004-05-12

Family

ID=26962574

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15820102A IL158201A0 (en) 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Country Status (18)

Country Link
US (1) US20030105141A1 (xx)
EP (1) EP1379279A1 (xx)
JP (1) JP2004530669A (xx)
KR (1) KR20040018355A (xx)
CN (1) CN1516601A (xx)
AR (1) AR033221A1 (xx)
AU (1) AU2002305175B2 (xx)
BR (1) BR0208994A (xx)
CA (1) CA2444220A1 (xx)
CZ (1) CZ20032792A3 (xx)
EA (1) EA008103B1 (xx)
IL (1) IL158201A0 (xx)
MX (1) MXPA03009411A (xx)
NO (1) NO20034629L (xx)
NZ (1) NZ528741A (xx)
PE (1) PE20021145A1 (xx)
PL (1) PL364524A1 (xx)
WO (1) WO2002083177A1 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1344523A1 (en) * 2002-03-11 2003-09-17 Warner-Lambert Company Ibuprofen solution for hard gelatin capsules
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
WO2004073492A2 (en) * 2003-02-14 2004-09-02 Massachusetts Eye And Ear Infirmary Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
PL2279729T3 (pl) * 2003-07-17 2017-02-28 Banner Life Sciences Llc Preparaty o kontrolowanym uwalnianiu
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
WO2005123043A2 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
SG164378A1 (en) * 2005-02-17 2010-09-29 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
EP1959935A2 (en) * 2005-10-26 2008-08-27 Banner Pharmacaps Inc. Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
JP5406529B2 (ja) 2005-10-26 2014-02-05 バナー ファーマキャプス， インコーポレイテッド カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム
EP2207531B1 (en) * 2007-09-27 2012-04-04 Wockhardt Limited Self-emulsifying pharmaceutical compositions of rhein or diacerein
BRPI0922806B8 (pt) * 2008-12-03 2021-05-25 Astellas Deutschland Gmbh composição farmacêutica oral compreendendo bendamustina
WO2011047259A1 (en) 2009-10-16 2011-04-21 Glaxosmithkline Llc Compositions
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
PT2575784T (pt) * 2010-06-02 2018-10-26 Astellas Deutschland Gmbh Formas de dosagem oral de bendamustina
EP2392319A1 (en) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
WO2013058303A1 (ja) * 2011-10-18 2013-04-25 ラクオリア創薬株式会社 医薬組成物
JP6389190B2 (ja) * 2013-01-14 2018-09-12 インファースト ヘルスケア リミテッド 固溶体組成物および慢性炎症における使用
WO2014117999A1 (en) * 2013-02-04 2014-08-07 Biocopea Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
CN109953954A (zh) 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
CN113750043A (zh) * 2021-09-18 2021-12-07 山东省药学科学院 一种塞来昔布自乳化口服液及其制备方法
WO2024142089A1 (en) * 2022-12-27 2024-07-04 Cipla Limited Injectable compositions of celecoxib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100229343B1 (ko) * 1993-11-30 1999-11-01 윌리암스 로저 에이 염증치료용 치환 피라졸일벤젠술폰아미드
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
AU750125B2 (en) * 1997-08-27 2002-07-11 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
AU2001282886A1 (en) * 2000-07-13 2002-01-30 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain

Also Published As

Publication number Publication date
AU2002305175B2 (en) 2007-07-12
NO20034629D0 (no) 2003-10-16
US20030105141A1 (en) 2003-06-05
EA008103B1 (ru) 2007-04-27
NO20034629L (no) 2003-12-10
EA200301019A1 (ru) 2004-06-24
NZ528741A (en) 2005-09-30
AR033221A1 (es) 2003-12-10
PL364524A1 (en) 2004-12-13
EP1379279A1 (en) 2004-01-14
CZ20032792A3 (cs) 2004-04-14
JP2004530669A (ja) 2004-10-07
CN1516601A (zh) 2004-07-28
PE20021145A1 (es) 2003-01-16
BR0208994A (pt) 2004-04-27
WO2002083177A1 (en) 2002-10-24
MXPA03009411A (es) 2004-01-29
CA2444220A1 (en) 2002-10-24
KR20040018355A (ko) 2004-03-03

Similar Documents

Publication Publication Date Title
IL158201A0 (en) Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine
IL216686A (en) Ritonavir-containing drug solution and organic solvent containing a mixture of long fatty acids and water
ITMI20021660A1 (it) Sistema di somministrazione di farmaco bioadesivo
CY2013023I1 (el) Φαρμακο για την υπερδραστηρια ουροδοχο κυστη περιλαμβανον παραγωγο ανιλιδιου οξικου οξεος ως το ενεργο συστατικο
NO20040178L (no) Farmasoytisk formulering innebefattende en protonpumpeinhibitor og syrenoytraliserende midler
LU92419I2 (fr) Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
NO20031797L (no) Heteroarylalkylpiperazin-derivater som fettsyreoksidasjonsinhibitorer
HRP20050458A2 (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
SI1245568T1 (sl) Sulfonilni derivati aminokislin in njihova uporaba kot inhibitorji depeptidil-peptidaze iv (dpp iv)
HRP20040545A2 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
PL372215A1 (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
IL158200A0 (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant
EP1330238A4 (en) PHARMACEUTICAL FORMULATIONS CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND PROTON PUMP INHIBITOR
IL170316A (en) Cycloalkyl-methoxy substituted acetic acid derivatives and pharmaceutical compositions comprising them
HUP0303810A3 (en) Carboxylic acid derivative and salt thereof and pharmaceutical compositions containing them
CY1114210T1 (el) Απο του στοματος μορφη δοσολογιας περιλαμβανουσα αναστολεα pde 4 ως δραστικο συστατικο και πολυβινυλοπυρρολιδονη ως εκδοχο
NO20040564L (no) Karboksylsyrederivatforbindelser og legemidler omfattende disse forbindelser som den aktive bestanddel
IL172167A0 (en) Pharmaceutically useful salts of carboxylic acid derivatives
IL208891A0 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
EP1246608A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES WITH LOW WATER SOLUBILITY
AR079399A2 (es) Procedimientos para preparar bifenazato
WO2004009583A3 (en) Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
AU2001278986A1 (en) 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors
DK1678162T3 (da) P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne
AU3408901A (en) Cancer remedy comprising anthranilic acid derivative as active ingredient